CHRISTOPHER STALLARD: Open Payments
NPI 1134480908 · SAN ANGELO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,478 in 117 payments from 16 companies in 2025. Trend: 2023 $2,478 · 2024 $2,562 · 2025 $2,478
Food & beverage: $2,342Education: $136
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 22 | $580 |
| GlaxoSmithKline, LLC. | 28 | $408 |
| Regeneron Healthcare Solutions, Inc. | 13 | $352 |
| Verona Pharma, Inc. | 12 | $268 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 15 | $259 |
| GENZYME CORPORATION | 6 | $142 |
| Insmed, Inc. | 6 | $120 |
| Vifor Pharma, Inc. | 4 | $104 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $75 |
| Grifols USA, LLC | 2 | $47 |
Products named: DUPIXENT, NUCALA, Ohtuvayre, BREZTRI, TEZSPIRE, OFEV, TRELEGY ELLIPTA, Arikayce.
Industry payments across TX — which companies pay providers there.
